logo for CODX

CODX • NASDAQ

Co-Diagnostics, Inc.

$5.07

+ Add to Watchlist

Stock Details

Market Cap 5,659,367
Day Change 1.36 (36.66%)
Volume 10,017,872
Avg Volume 5,309,950
Price Range 1.26-46.5

Overview

Country US
Sector Healthcare
Industry Medical - Devices
Exchange NASDAQ

Company Profile

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.

Financial Overview

52 Week High 46.5
52 Week High Date 2025-10-27
52 Week Low 1.26
52 Week Low Date 2026-05-15
10D Avg Trading Vol 23.95364
YTD Price Return Daily 0.1976
MTD Price Return Daily 227.0968

Cash Flow

TTM/Share -1.40726
Annual/Share -14.2418
Quarterly/Share -8.0467

Price-to-Earnings

Annual Ratio 3.8686
Quarterly Ratio 2.2831
TTM

Revenue

3Y Growth -73.7
5Y Growth -61.6
Annual/Share 190.27
TTM/Share 0.3187
5Y Share Growth -29.37

Earnings Per Share

Annual -35.2548
3Y Growth
5Y Growth
Quarterly YOY Growth

Price-to-Book

Ratio 1.1385
Annual Ratio 0.4977
TTM 0.4177